...
首页> 外文期刊>Toxicologic pathology >Assessment of Cardiac Troponin I Responses in Nonhuman Primates during Restraint, Blood Collection, and Dosing in Preclinical Safety Studies
【24h】

Assessment of Cardiac Troponin I Responses in Nonhuman Primates during Restraint, Blood Collection, and Dosing in Preclinical Safety Studies

机译:临床前安全性研究期间,评估血压印刷物中的心肌肌钙蛋白I的反应

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Limited information has been published on the use of cardiac troponin I (cTnI) as a biomarker of cardiac injury in monkeys. The purpose of these studies was to characterize the cTnI response seen in cynomolgus macaques during routine dosing and blood collection procedures typically used in preclinical safety studies and to better understand the pathogenesis of this response. We measured cTnI using two different methods, the Siemens Immulite cTnI assay and the more sensitive Siemens Troponin I-Ultra assay. We were able to demonstrate that after oral, subcutaneous, or intravenous dosing of common vehicles, as well as serial chair restraint for venipuncture blood collection, that minimal to mild transient increases in cTnI could be detected in monkeys with both assays. cTnI values typically peaked at 2, 3, 4, or 6 hr after sham dosing and returned to baseline at 22 or 24 hr. In addition, marked increases in heart rate (HR) and blood pressure (BP) occurred in monkeys during the restraint procedures, which likely initiated the cTnI release in these animals. Monkeys that were very well acclimated to the chairing procedures and had vascular access ports for blood sampling did not have marked increases in HRs and BP or increases in cTnI.
机译:已经发表了有限的信息,用于使用心肌肌钙蛋白I(CTNI)作为猴子心脏损伤的生物标志物。这些研究的目的是在常规剂量给药和血液收集程序期间表征在Cynomolgus MAKQUES中看到的CTNI反应,通常用于临床前安全性研究,并更好地理解这种反应的发病机制。我们使用两种不同的方法测量CTNI,西门子免疫性CTNI测定和更敏感的西门子肌钙蛋白I-Ultra测定。我们能够证明在口服,皮下或静脉给药的普通型载体中,以及静脉血血液收集的串行椅子克制,可以在猴子中检测到CTNI中的轻度瞬态增加的最小瞬态增加。 CTNI值通常在假时剂量后在2,3,4或6小时达到峰值,并在22或24小时以22或24小时返回基线。此外,在约束程序期间,在猴子期间,心率(HR)和血压(BP)的显着增加,这可能引发了这些动物中的CTNI释放。猴子适应担任主持程序,并且对血液采样的血管进入港口没有显着的人力资源和BP增加或CTNI增加。

著录项

  • 来源
    《Toxicologic pathology》 |2017年第2期|共9页
  • 作者单位

    Pfizer Global Res &

    Dev Drug Safety Res &

    Dev Eastern Point Rd 8274-1203 Groton CT 06340 USA;

    Pfizer Global Res &

    Dev Drug Safety Res &

    Dev Eastern Point Rd 8274-1203 Groton CT 06340 USA;

    Pfizer Global Res &

    Dev Drug Safety Res &

    Dev Eastern Point Rd 8274-1203 Groton CT 06340 USA;

    Pfizer Global Res &

    Dev Drug Safety Res &

    Dev Eastern Point Rd 8274-1203 Groton CT 06340 USA;

    Pfizer Global Res &

    Dev Drug Safety Res &

    Dev Eastern Point Rd 8274-1203 Groton CT 06340 USA;

    Pfizer Global Res &

    Dev Drug Safety Res &

    Dev Eastern Point Rd 8274-1203 Groton CT 06340 USA;

    Pfizer Global Res &

    Dev Drug Safety Res &

    Dev Eastern Point Rd 8274-1203 Groton CT 06340 USA;

    Pfizer Global Res &

    Dev Drug Safety Res &

    Dev Eastern Point Rd 8274-1203 Groton CT 06340 USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 毒物学(毒理学);
  • 关键词

    cardiac troponin I; cynomolgus; biomarker; heat rate; restraint;

    机译:心肌肌钙蛋白I;cynomolgus;生物标志物;热速率;克制;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号